Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

This Quarterly Report on Form 10-Q contains statements which, to the extent they are not statements of historical fact, constitute “forward-looking statements.” Such forward-looking statements about our business and expectations within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), include statements relating to, among other things, our expectations regarding revenue recognition timing and amounts; business trends, earnings, and other measures of financial performance; projected impact of foreign currency exchange rates and hedging activities; realizability of assets; future cash flow and uses of cash; future repurchases of common stock; future levels of indebtedness and capital spending; the working capital and liquidity outlook; critical accounting estimates; deductibility of goodwill; inflation; and projected impacts of tariff and trade policy changes and uncertainty. Forward-looking statements can be identified by the use of words such as “expects,” “may,” “anticipates,” “intends,” “would,” “will,” “plans,” “believes,” “estimates,” “should,” “project,” and similar words and expressions. These forward-looking statements are intended to provide our current expectations or forecasts of future events; are based on current estimates, projections, beliefs, and assumptions; and are not guarantees of future performance. Actual events or results may differ materially from those described in the forward-looking statements. These forward-looking statements involve a number of risks and uncertainties, including, among other things, the adverse impact, and the duration, of macroeconomic events, conditions, and uncertainties, such as geopolitical instability (including wars, terrorist attacks, and armed conflicts), general economic uncertainty, changes in U.S. and other countries’ tariff and trade policies, inflationary pressures, severe weather and other natural conditions, and supply chain challenges on our business, results of operations, liquidity, financial condition, and stock price, as well as the other matters described under the headings “Business,” “Risk Factors,” “Legal Proceedings,” “Management's Discussion and Analysis of Financial Condition and Results of Operations,” and “Quantitative and Qualitative Disclosure About Market Risk” in our 2024 Annual Report and in the corresponding sections of this Quarterly Report on Form 10-Q, as well as those described from time to time in our other periodic reports filed with the SEC.

Any forward-looking statements represent our estimates only as of the day this Quarterly Report on Form 10-Q was filed with the SEC and should not be relied upon as representing our estimates as of any subsequent date. From time to time, oral or written forward-looking statements may also be included in other materials released to the public, and they are subject to the risks and uncertainties described or cross-referenced in this section. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates or expectations change.

You should read the following discussion and analysis in conjunction with our 2024 Annual Report that includes additional information about us, our results of operations, our financial position, and our cash flows, and with our unaudited condensed consolidated financial statements and related notes included in “Part I. Item 1. Financial Statements” of this Quarterly Report on Form 10-Q.

Our fiscal quarter ended on June 30. Unless otherwise stated, the analysis and discussion of our financial condition and results of operations below, including references to growth and organic growth and increases and decreases, are being compared to the equivalent prior-year periods.

Business Overview

We develop, manufacture, and distribute products and provide services primarily for the companion animal veterinary, livestock, poultry and dairy, and water testing sectors. We also provide human medical point-of-care diagnostics. Our primary products and services are:

• Point-of-care veterinary diagnostic products, comprised of instruments, consumables, and rapid assay test kits;

• Veterinary reference laboratory diagnostic and consulting services;

• Practice management and diagnostic imaging systems and services used by veterinarians;

• Health monitoring, biological materials testing, laboratory diagnostic instruments, and services used by the biomedical research community;

• Diagnostic and health-monitoring products for livestock, poultry, and dairy;

• Products that test water for certain microbiological contaminants; and

• Point-of-care electrolytes and blood gas analyzers for the human medical diagnostics sector.

Description of Operating Segments. We operate primarily through three operating segments: diagnostic and information management-based products and services for the companion animal veterinary industry, which we refer to as the Companion Animal Group (“CAG”); water quality products (“Water”); and diagnostic tests, services, and related

instrumentation that are used to manage the health status of livestock and poultry, to improve producer efficiency, and to ensure the quality and safety of milk, which we refer to as Livestock, Poultry and Dairy (“LPD”). Other information combines and presents our human medical diagnostic products business (“OPTI Medical”) with our out-licensing arrangements because they do not meet the quantitative or qualitative thresholds for reportable segments. Foreign currency transaction gains and losses for all operating segments are also reported within Other.

Currency Impact, Tariff and Trade Policies, U.S. Tax Law Changes, and Other Items

Currency Impact. Refer to “Part I, Item 3. Quantitative and Qualitative Disclosures about Market Risk” included in this Quarterly Report on Form 10-Q for additional information regarding the impact of foreign currency exchange rates.

Changes in Tariff and Trade Policies. Although we manufacture many of our companion animal and Water testing products, as well as certain of our LPD testing products, in the United States, we rely on third-party suppliers located in the United States and other regions (such as Europe and Asia Pacific) for certain components, raw materials, and consumables used in or with our products. In addition, as a global business, our products and services are sold in more than 175 countries. For the year ended December 31, 2024, approximately 35% of our overall revenues were attributable to sales of products and services to customers outside the United States, with less than 1% of our overall revenues attributable to sales of products and services to customers domiciled in China. Accordingly, changes in tariff and trade policies may adversely affect our business, financial condition, and operating results.

The U.S. government previously announced changes to its trade policy, including increasing tariffs on imports, in some cases significantly, and potentially renegotiating or terminating its existing trade agreements. Imposition of certain country-specific tariffs are uncertain and subject to negotiations, and these actions, as well as retaliatory tariffs imposed by other countries on U.S. exports and continuing uncertainty regarding tariff and trade policies have led to volatility and uncertainty in global markets. Continuing tariff and trade policy uncertainty may lead to sustained volatility and uncertainty in U.S. and global financial and economic conditions, increased inflation, diminished expectations for economic growth, and actual or perceived economic weakness, which could result in reduced demand for our products and services.

While we are working to optimize operations and inventory management to the extent feasible, to help mitigate and reduce the potential impact from changes in tariff and trade policies, any imposed tariffs (including retaliatory tariffs) and our mitigation activities may cause our cost of goods to increase, our profit margins to decrease, or our products to become less competitive or less available in the applicable region. We are continuing to monitor the dynamic trade environment and evaluate these developments and our ability to offset some portion of these costs and otherwise mitigate the impact on our business, financial condition, and operating results.

U.S. Tax Law Changes. On July 4, 2025, H.R. 1 of the 119th Congress, also referred to as the “One Big Beautiful Bill Act” (“OBBBA”), was signed into law. The OBBBA includes significant changes to federal tax law, such as the permanent extension of certain expiring provisions of the Tax Cuts and Jobs Act of 2017, as well as modifications to the international tax framework and other regulatory provisions. We are in the process of evaluating the impact of the OBBBA on our financial statements and results of operations.

Other Items. Refer to “Part I, Item 1. Business - Patents and Licenses” and “Part II. Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in our 2024 Annual Report for additional information regarding trends in companion animal healthcare, distributor purchasing and inventories, economic conditions, geopolitical conflict effects and patent expiration.

Critical Accounting Estimates and Assumptions

The discussion and analysis of our financial condition and results of operations is based upon our unaudited condensed consolidated financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, and expenses, and related disclosure of contingent assets and liabilities. We evaluate our estimates on an ongoing basis. We base our estimates on historical experience and on various assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates. The critical accounting policies and the significant judgments and estimates used in the preparation of our unaudited condensed consolidated financial statements for the three and six months ended June 30, 2025, are consistent with those discussed in our 2024 Annual Report in the section under the heading “Part II. Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations - Critical Accounting Estimates and Assumptions.”

Recent Accounting Pronouncements

For more information regarding the impact that recent accounting standards and amendments will have on our consolidated financial statements, refer to Note 2 to the unaudited condensed consolidated financial statements in “Part I. Item 1. Financial Statements” of this Quarterly Report on Form 10-Q.

Non-GAAP Financial Measures

Organic Revenue Growth. The following revenue analysis and discussion focuses on organic revenue growth, and references in this analysis and discussion to “revenue,” “revenues,” or “revenue growth” are references to “organic revenue growth.” Organic revenue growth is a non-GAAP financial measure and represents the percentage change in revenue during the three and six months ended June 30, 2025, compared to the same period for the prior year, net of the effect of changes in foreign currency exchange rates, certain business acquisitions, and divestitures. Organic revenue growth should be considered in addition to, and not as a replacement for, or as a superior measure to, revenue growth reported in accordance with U.S. GAAP, and may not be comparable to similarly titled measures reported by other companies. Management believes that reporting organic revenue growth provides useful information to investors by facilitating easier comparisons of our revenue performance with prior and future periods and to the performance of our peers.

We exclude from organic revenue growth the effect of changes in foreign currency exchange rates because changes in foreign currency exchange rates are not under management’s control, are subject to volatility, and can obscure underlying business trends. We calculate the impact on revenue resulting from changes in foreign currency exchange rates by applying the difference between the weighted average exchange rates during the current-year period and the comparable prior-year period to foreign currency denominated revenues for the prior-year period.

We also exclude from organic revenue growth the effect of certain business acquisitions and divestitures because the nature, size, and number of these transactions can vary dramatically from period to period, and because they either require or generate cash as an inherent consequence of the transaction, and therefore can also obscure underlying business and operating trends. We consider acquisitions to be a business when all three elements of inputs, processes, and outputs are present, consistent with ASU 2017-01, “Business Combinations: (Topic 805) Clarifying the Definition of a Business.” In a business combination, if substantially all the fair value of the assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets, we do not consider these assets to be a business. A typical acquisition that we do not consider a business is a customer list asset acquisition, which does not have all elements necessary to operate a business, such as employees or infrastructure. We believe the efforts required to convert and retain these acquired customers are similar in nature to our existing customer base and therefore are included in organic revenue growth. The percentage change in revenue resulting from business acquisitions represents revenues during the current-year period, limited to the initial twelve months from the date of the acquisition, that are directly attributable to business acquisitions.

Segment Income from Operations. We report segment income from operations in our discussion of the results of the operations of our segments below. Segment income from operations is a non-GAAP financial measure that adjusts for the impact of foreign currency transaction gains and losses and should be considered in addition to, and not as a replacement for, income from operations. We exclude foreign currency transaction gains and losses for each reportable segment (CAG, Water, and LPD) from segment income from operations and report the full amount of foreign currency transaction gains and losses in Other. We believe that reporting segment income from operations provides supplemental analysis to help investors further evaluate each reportable segment’s business performance by excluding foreign currency transaction gains and losses, which are centrally managed by our corporate treasury function and which we do not consider relevant for assessing the results of each reportable segment’s operations. In addition, we believe that reporting segment income from operations provides information to investors regarding key metrics that are used by management, including our CODM, in evaluating the performance of each reportable segment.

The reconciliation of these non-GAAP financial measures is as follows:

(dollars in thousands)						For the Three Months Ended June 30,
						2025																		2024
						Income from Operations						Impact from Foreign Currency						Segment and Other Income from Operations						Income from Operations						Impact from Foreign Currency						Segment and Other Income from Operations
CAG						$	347,983					$	494					$	348,477					$	240,687					$	863					$	241,550
Water						24,606						36						24,642						20,439						65						20,504
LPD						(543)						38						(505)						1,426						73						1,499
Other						1,000						(568)						432						1,249						(1,001)						248
Total						$	373,046					$	—					$	373,046					$	263,801					$	—					$	263,801

(dollars in thousands)						For the Six Months Ended June 30,
						2025																		2024
						Income from Operations						Impact from Foreign Currency						Segment and Other Income from Operations						Income from Operations						Impact from Foreign Currency						Segment and Other Income from Operations
CAG						$	642,554					$	1,078					$	643,632					$	519,573					$	1,673					$	521,246
Water						45,380						79						45,459						39,811						123						39,934
LPD						(462)						82						(380)						2,227						138						2,365
Other						2,108						(1,239)						869						1,148						(1,934)						(786)
Total						$	689,580					$	—					$	689,580					$	562,759					$	—					$	562,759

Other Non-GAAP Financial Measures. We also use Adjusted EBITDA, gross debt, net debt, gross debt to Adjusted EBITDA ratio, and net debt to Adjusted EBITDA ratio, all of which are non-GAAP financial measures that should be considered in addition to, and not as a replacement for, financial measures presented according to U.S. GAAP. Management believes that reporting these non-GAAP financial measures provides supplemental analysis to help investors further evaluate our business performance and available borrowing capacity under our Credit Facility.

Results of Operations

Three Months Ended June 30, 2025, Compared to Three Months Ended June 30, 2024

Total Company. The following table presents total Company revenue by operating segment:

						For the Three Months Ended June 30,
Net Revenue (dollars in thousands)						2025						2024						Dollar Change						Reported Revenue Growth (1)						Percentage Change from Currency						Percentage Change from Acquisitions						Organic Revenue Growth (1)
CAG						$	1,022,443					$	922,298					$	100,145					10.9		%				1.2		%				—						9.7		%
United States						684,497						628,684						55,813						8.9		%				—						—						8.9		%
International						337,946						293,614						44,332						15.1		%				3.8		%				—						11.3		%
Water						$	51,001					$	46,726					$	4,275					9.1		%				0.8		%				—						8.4		%
United States						26,090						24,461						1,629						6.7		%				—						—						6.7		%
International						24,911						22,265						2,646						11.9		%				1.7		%				—						10.2		%
LPD						$	31,762					$	30,306					$	1,456					4.8		%				2.2		%				—						2.6		%
United States						5,767						5,115						652						12.8		%				—						—						12.8		%
International						25,995						25,191						804						3.2		%				2.6		%				—						0.6		%
Other						$	4,251					$	4,248					$	3					0.1		%				—						—						0.1		%
Total Company						$	1,109,457					$	1,003,578					$	105,879					10.6		%				1.2		%				—						9.3		%
United States						717,869						660,146						57,723						8.7		%				—						—						8.7		%
International						391,588						343,432						48,156						14.0		%				3.6		%				—						10.5		%

(1)Reported revenue growth and organic revenue growth may not recalculate due to rounding.

Total Company Revenue. The increase in revenue reflected growth in CAG Diagnostics recurring revenue, including benefits from higher realized prices and higher volumes, which were supported by new business gains, our expanded menu of available tests, and high customer retention rates, partially offset by constraints from macroeconomic and sector headwinds. Instrument revenue gains were primarily due to the placements of our recently launched IDEXX inVue DxTM Analyzer. Higher volumes and price gains in recurring veterinary software, services, and diagnostic imaging also contributed to revenue growth. Higher revenue in Water revenue was primarily due to the benefit of realized price increases and increased volumes. The increase in LPD revenue was primarily due to higher realized prices and higher volume. The change in foreign currency exchange rates increased revenue growth by 1.2%.

The following table presents total Company results of operations:

						For the Three Months Ended June 30,																								Change
Total Company - Results of Operations (dollars in thousands)						2025						Percent of Revenue						2024						Percent of Revenue						Amount						Percentage
Revenues						$	1,109,457											$	1,003,578											$	105,879					10.6		%
Cost of revenue						414,725												384,419												30,306						7.9		%
Gross profit						694,732						62.6		%				619,159						61.7		%				75,573						12.2		%
Operating expenses:
Sales and marketing						161,107						14.5		%				142,665						14.2		%				18,442						12.9		%
General and administrative						98,681						8.9		%				157,243						15.7		%				(58,562)						(37.2		%)
Research and development						61,898						5.6		%				55,450						5.5		%				6,448						11.6		%
Total operating expenses						321,686						29.0		%				355,358						35.4		%				(33,672)						(9.5		%)
Income from operations						$	373,046					33.6		%				$	263,801					26.3		%				$	109,245					41.4		%

Gross Profit. Gross profit increased due to higher revenue and a 90 basis point increase in the gross profit margin. The increase in the gross profit margin reflected proportionately higher IDEXX VetLab consumable volume growth, productivity improvements, and the benefit from net price realization, offsetting the inflationary impacts. The overall change in foreign currency exchange rates decreased the gross profit margin by approximately 20 basis points, including the impact of hedge losses during the current period compared to hedge gains in the prior period.

Operating Expenses. Sales and marketing expense increased primarily due to higher personnel-related and commercial costs. General and administrative expense decreased primarily due to a $61.5 million expense in the prior year related to a litigation matter that was concluded in April 2025, partially offset by higher personnel-related and information technology costs. Research and development expense increased primarily due to higher personnel-related costs. The change in foreign currency exchange rates increased operating expense growth by less than 1.0%.

Companion Animal Group

The following table presents revenue by product and service category for CAG:

						For the Three Months Ended June 30,
Net Revenue (dollars in thousands)						2025						2024						Dollar Change						Reported Revenue Growth (1)						Percentage Change from Currency						Percentage Change from Acquisitions						Organic Revenue Growth (1)
CAG Diagnostics recurring revenue:						$	877,995					$	808,454					$	69,541					8.6		%				1.2		%				—						7.4		%
IDEXX VetLab consumables						375,112						325,348						49,764						15.3		%				1.7		%				—						13.6		%
Rapid assay products						100,240						103,290						(3,050)						(3.0		%)				0.4		%				—						(3.3		%)
Reference laboratory diagnostic and consulting services						367,694						347,373						20,321						5.9		%				1.1		%				—						4.8		%
CAG diagnostics services and accessories						34,949						32,443						2,506						7.7		%				1.7		%				—						6.0		%
CAG Diagnostics capital - instruments						$	58,600					$	35,292					$	23,308					66.0		%				3.5		%				—						62.5		%
Veterinary software, services and diagnostic imaging systems						$	85,848					$	78,552					$	7,296					9.3		%				0.1		%				—						9.2		%
Recurring revenue						68,954						63,117						5,837						9.2		%				0.2		%				—						9.1		%
Systems and hardware						16,894						15,435						1,459						9.5		%				—						—						9.4		%
Net CAG revenue						$	1,022,443					$	922,298					$	100,145					10.9		%				1.2		%				—						9.7		%

(1) Reported revenue growth and organic revenue growth may not recalculate due to rounding.

CAG Diagnostics Recurring Revenue. The increase in CAG Diagnostics recurring revenue was primarily due to higher volumes in IDEXX VetLab consumables and reference laboratory testing, constrained by macroeconomic and sector headwinds, and higher realized prices. The change in foreign currency exchange rates increased revenue growth by 1.2%.

The increase in IDEXX VetLab consumables revenue was primarily due to higher test volumes and price realization. Volume gains were supported by increases in testing across regions, including the benefits from 10% growth in our active installed base of premium instruments, which reflected new customers and continued high customer retention rates, and our expanded menu of available tests, including the launch of the pancreatic lipase test on our Catalyst instrument platform. The change in foreign currency exchange rates increased revenue growth by 1.7%.

The decrease in rapid assay revenue resulted primarily from a shift of customers’ pancreatic lipase testing to our Catalyst instrument platform, as well as lower clinical visits in the U.S., partially offset by higher price realization. The change in foreign currency exchange rates increased revenue growth by 0.4%.

The increase in reference laboratory diagnostic and consulting services revenue was due to higher testing volumes, primarily in the U.S. and, to a lesser extent, Europe, and from global price realization. The change in foreign currency exchange rates increased revenue growth by 1.1%.

The increase in CAG Diagnostics services and accessories revenue was primarily a result of the 10% growth in our active installed base of premium instruments. The change in foreign currency exchange rates increased revenue growth by 1.7%.

CAG Diagnostics Capital – Instrument Revenue. The increase in instrument revenue was primarily due to placements of our recently launched IDEXX inVue Dx Analyzer, as well as program pricing effects, partially offset by lower placements of other premium instruments. The change in foreign currency exchange rates increased revenue growth by 3.5%.

Veterinary Software, Services and Diagnostic Imaging Systems Revenue. The increase in recurring revenue was primarily due to higher subscription and support services volume from our expanded installed base and higher realized prices. The increase in our systems and hardware revenue was primarily due to higher diagnostic imaging system sales. The change in foreign currency exchange rates increased revenue growth by 0.1%.

The following table presents the CAG segment results of operations:

						For the Three Months Ended June 30,																								Change
Results of Operations (dollars in thousands)						2025						Percent of Revenue						2024						Percent of Revenue						Amount						Percentage
Revenues						$	1,022,443											$	922,298											$	100,145					10.9		%
Cost of revenue						380,341												353,227												27,114						7.7		%
Gross profit						642,102						62.8		%				569,071						61.7		%				73,031						12.8		%
Segment operating expenses:
Sales and marketing						146,896						14.4		%				129,435						14.0		%				17,461						13.5		%
General and administrative						89,478						8.8		%				147,028						15.9		%				(57,550)						(39.1		%)
Research and development						57,251						5.6		%				51,058						5.5		%				6,193						12.1		%
Total segment operating expenses						293,625						28.7		%				327,521						35.5		%				(33,896)						(10.3		%)
Segment income from operations						$	348,477					34.1		%				$	241,550					26.2		%				$	106,927					44.3		%

Gross Profit. Gross profit increased due to higher revenue and a 110 basis point increase in the gross profit margin. The increase in the gross profit margin reflected the proportionately higher IDEXX VetLab consumable volume growth, productivity improvements, and the benefits from net price realization, offsetting the inflationary cost impacts. The overall change in foreign currency exchange rates decreased the gross profit margin by approximately 10 basis points, including the impact of hedge losses during the current period compared to hedge gains in the prior period.

Segment Operating Expenses. Sales and marketing expense increased primarily due to higher personnel-related and commercial costs. General and administrative expense decreased primarily due to a $61.5 million expense in the prior year related to a litigation matter that concluded in April 2025, partially offset by higher personnel-related and information technology costs. Research and development expense increased primarily due to higher personnel-related costs. The change in foreign currency exchange rates increased operating expense growth by less than 1%.

Water

The following table presents the Water segment results of operations:

						For the Three Months Ended June 30,																								Change
Results of Operations (dollars in thousands)						2025						Percent of Revenue						2024						Percent of Revenue						Amount						Percentage
Revenues						$	51,001											$	46,726											$	4,275					9.1		%
Cost of revenue						15,490												14,652												838						5.7		%
Gross profit						35,511						69.6		%				32,074						68.6		%				3,437						10.7		%
Segment operating expenses:
Sales and marketing						6,065						11.9		%				5,971						12.8		%				94						1.6		%
General and administrative						3,345						6.6		%				4,324						9.3		%				(979)						(22.6		%)
Research and development						1,459						2.9		%				1,275						2.7		%				184						14.4		%
Total segment operating expenses						10,869						21.3		%				11,570						24.8		%				(701)						(6.1		%)
Segment income from operations						$	24,642					48.3		%				$	20,504					43.9		%				$	4,138					20.2		%

Revenue. The increase in revenue was primarily due to higher realized prices and higher volumes. The increase in volumes was due to placements of instruments, including the placements of our new UA Viewer Plus, and higher testing volumes, primarily in Europe and Asia Pacific. The change in foreign currency exchange rates increased revenue by approximately 0.8%.

Gross Profit. Gross profit increased due to higher revenue, as well as a 100 basis point increase in the gross profit margin. The increase in the gross profit margin was primarily due to higher realized prices, and to a lesser extent, lower product costs. These increases were partially offset by higher distribution costs. The change in foreign currency exchange rates decreased the gross profit margin by approximately 50 basis points, including the impact of hedge losses during the current period compared to hedge gains in the prior period.

Segment Operating Expenses. Sales and marketing expense increased primarily due to higher travel and meeting costs partially offset by lower personnel-related costs. General and administrative expense decreased primarily due to lower bad debt expense. Research and development expense increased primarily due to higher personnel-related costs. The change in foreign currency exchange rates was not significant to operating expense growth.

Livestock, Poultry and Dairy

The following table presents the LPD segment results of operations:

						For the Three Months Ended June 30,																								Change
Results of Operations (dollars in thousands)						2025						Percent of Revenue						2024						Percent of Revenue						Amount						Percentage
Revenues						$	31,762											$	30,306											$	1,456					4.8		%
Cost of revenue						16,833												14,748												2,085						14.1		%
Gross profit						14,929						47.0		%				15,558						51.3		%				(629)						(4.0		%)
Segment operating expenses:
Sales and marketing						7,847						24.7		%				6,988						23.1		%				859						12.3		%
General and administrative						4,555						14.3		%				4,179						13.8		%				376						9.0		%
Research and development						3,032						9.5		%				2,892						9.5		%				140						4.8		%
Total segment operating expenses						15,434						48.6		%				14,059						46.4		%				1,375						9.8		%
Segment income from operations						$	(505)					(1.6		%)				$	1,499					4.9		%				$	(2,004)					(133.7		%)

Revenue. The increase in revenue was primarily due to higher realized prices and an increase in test volumes in Asia Pacific and North America, partially offset by lower volumes in Europe. The change in foreign currency exchange rates increased revenue growth by 2.2%.

Gross Profit. The decrease in gross profit was primarily due to a 430 basis point decrease in the gross profit margin, partially offset by higher revenue. The decrease in the gross profit margin was primarily due to higher product and related costs, partially offset by higher realized prices. The change in foreign currency exchange rates decreased the gross profit margin by approximately 180 basis points, including the impact of hedge losses during the current period compared to hedge gains in the prior period.

Segment Operating Expenses. Sales and marketing expense increased primarily due to higher personnel-related costs. General and administrative expense increased primarily due to personnel-related costs and higher bad debt expense. Research and development expense increased primarily due to higher facilities costs. The change in foreign currency exchange rates increased operating expense growth by approximately 2%.

Other

The following table presents the Other results of operations:

						For the Three Months Ended June 30,																								Change
Results of Operations (dollars in thousands)						2025						Percent of Revenue						2024						Percent of Revenue						Amount						Percentage
Revenues						$	4,251											$	4,248											$	3					0.1		%
Cost of revenue						2,061												1,792												269						15.0		%
Gross profit						2,190						51.5		%				2,456						57.8		%				(266)						(10.8		%)
Other operating expenses:
Sales and marketing						299						7.0		%				271						6.4		%				28						10.3		%
General and administrative						1,303						30.7		%				1,712						40.3		%				(409)						(23.9		%)
Research and development						156						3.7		%				225						5.3		%				(69)						(30.7		%)
Total Other operating expenses						1,758						41.4		%				2,208						52.0		%				(450)						(20.4		%)
Other income from operations						$	432					10.2		%				$	248					5.8		%				$	184					74.2		%

Revenue. Revenue increases from higher sales volumes of our OPTI Medical consumables and instruments were offset by lower royalty revenue.

Gross Profit. Gross profit decreased primarily due to a 630 basis point decrease in the gross profit margin. The decrease in the gross profit margin was largely due to higher product and freight costs. The change in foreign currency exchange rates did not have a significant impact on the gross profit margin.

Operating Expenses. Sales and marketing expense increased due to higher personnel-related costs. General and administrative expense decreased primarily due to lower foreign currency transaction losses compared to the prior year. Research and development expense decreased due to lower activities that were not attributable to our three reportable segments.

Non-Operating Items

Interest Expense and Income. Interest expense was $11.3 million for the three months ended June 30, 2025, as compared to $8.1 million for the same period during the prior year. The increase in interest expense was primarily due to higher average debt levels and, to a lesser extent, higher interest rates. Interest income was $0.6 million for the three months ended June 30, 2025, compared to $3.4 million for the same period during the prior year, primarily due to a decrease in money market investments.

Provision for Income Taxes. Our effective income tax rate was 18.9% for the three months ended June 30, 2025, compared to 21.5% for the three months ended June 30, 2024. The decrease in our effective tax rate was primarily due to an increase in tax benefits related to share-based compensation and the resolution of international tax audits.

Results of Operations

Six Months Ended June 30, 2025, Compared to Six Months Ended June 30, 2024

Total Company. The following table presents total Company revenue by operating segment:

						For the Six Months Ended June 30,
Net Revenue (dollars in thousands)						2025						2024						Dollar Change						Reported Revenue Growth (1)						Percentage Change from Currency						Percentage Change from Acquisitions						Organic Revenue Growth (1)
CAG						$	1,942,279					$	1,811,583					$	130,696					7.2		%				—						0.1		%				7.1		%
United States						1,308,386						1,230,879						77,507						6.3		%				—						0.1		%				6.2		%
International						633,893						580,704						53,189						9.2		%				0.1		%				—						9.1		%
Water						$	96,322					$	89,797					$	6,525					7.3		%				(0.6		%)				—						7.9		%
United States						49,593						46,660						2,933						6.3		%				—						—						6.3		%
International						46,729						43,137						3,592						8.3		%				(1.3		%)				—						9.6		%
LPD						$	60,358					$	58,511					$	1,847					3.2		%				(0.2		%)				—						3.4		%
United States						11,555						10,279						1,276						12.4		%				—						—						12.4		%
International						48,803						48,232						571						1.2		%				(0.2		%)				—						1.4		%
Other						$	8,925					$	7,782					$	1,143					14.7		%				—						—						14.7		%
Total Company						$	2,107,884					$	1,967,673					$	140,211					7.1		%				—						0.1		%				7.1		%
United States						1,372,730						1,291,155						81,575						6.3		%				—						0.1		%				6.2		%
International						735,154						676,518						58,636						8.7		%				—						—						8.7		%

(1)Reported revenue growth and organic revenue growth may not recalculate due to rounding.

Total Company Revenue. The increase in revenue reflected growth in CAG Diagnostics recurring revenue, including benefits from higher realized prices and higher volumes, which were supported by new business gains, our expanded menu of available tests, and high customer retention rates, partially offset by constraints from macroeconomic and sector headwinds. Instrument revenue gains were primarily due to the placements of our recently launched IDEXX inVue Dx Analyzer. Higher volumes and price gains in recurring veterinary software, services, and diagnostic imaging also contributed to revenue growth. Higher revenue in our Water business was primarily due to the benefit of realized price increases and increased volumes. The increase in LPD revenue was primarily due to higher realized prices and higher volumes. The increase in Other revenue was primarily due to higher volumes of our OPTI Medical consumables and instruments. Acquisitions increased revenue growth by 0.1%.

The following table presents total Company results of operations:

						For the Six Months Ended June 30,																								Change
Total Company - Results of Operations (dollars in thousands)						2025						Percent of Revenue						2024						Percent of Revenue						Amount						Percentage
Revenues						$	2,107,884											$	1,967,673											$	140,211					7.1		%
Cost of revenue						789,773												755,444												34,329						4.5		%
Gross profit						1,318,111						62.5		%				1,212,229						61.6		%				105,882						8.7		%
Operating expenses:
Sales and marketing						317,330						15.1		%				292,118						14.8		%				25,212						8.6		%
General and administrative						190,242						9.0		%				249,267						12.7		%				(59,025)						(23.7		%)
Research and development						120,959						5.7		%				108,085						5.5		%				12,874						11.9		%
Total operating expenses						628,531						29.8		%				649,470						33.0		%				(20,939)						(3.2		%)
Income from operations						$	689,580					32.7		%				$	562,759					28.6		%				$	126,821					22.5		%

Gross Profit. Gross profit increased due to higher revenue and a 90 basis point increase in the gross profit margin. The increase in the gross profit margin reflected proportionately higher IDEXX VetLab consumable volume growth, favorable instrument placement mix, and the benefit from net price realization, offsetting inflationary cost impacts. These increases in the gross profit margin were reduced by the business mix impact from high instrument revenue. The change in foreign currency exchange rates on the gross profit margin was not significant.

Operating Expenses. Sales and marketing expense increased primarily due to higher personnel-related and commercial costs. General and administrative expense decreased primarily due to a $61.5 million expense in the prior year related to a litigation matter, partially offset by a related reduction in accrued expense of approximately $9 million in the first quarter of the current period and by higher personnel-related and information technology costs. Research and development expense increased primarily due to higher personnel-related costs, as well as higher project costs. The change in foreign currency exchange rates was not significant to operating expense growth.

Companion Animal Group

The following table presents revenue by product and service category for CAG:

						For the Six Months Ended June 30,
Net Revenue (dollars in thousands)						2025						2024						Dollar Change						Reported Revenue Growth (1)						Percentage Change from Currency						Percentage Change from Acquisitions						Organic Revenue Growth (1)
CAG Diagnostics recurring revenue:						$	1,684,262					$	1,588,598					$	95,664					6.0		%				—						—						6.0		%
IDEXX VetLab consumables						719,891						642,277						77,614						12.1		%				—						—						12.1		%
Rapid assay products						184,274						189,605						(5,331)						(2.8		%)				(0.1		%)				—						(2.7		%)
Reference laboratory diagnostic and consulting services						712,100						691,711						20,389						2.9		%				0.1		%				—						2.9		%
CAG diagnostics services and accessories						67,997						65,005						2,992						4.6		%				—						—						4.6		%
CAG Diagnostics capital - instruments						$	90,594					$	69,384					$	21,210					30.6		%				0.4		%				—						30.1		%
Veterinary software, services and diagnostic imaging systems:						$	167,423					$	153,601					$	13,822					9.0		%				(0.2		%)				0.9		%				8.3		%
Recurring revenue						134,747						122,817						11,930						9.7		%				(0.2		%)				0.9		%				9.0		%
Systems and hardware						32,676						30,784						1,892						6.1		%				(0.2		%)				0.8		%				5.6		%
Net CAG revenue						$	1,942,279					$	1,811,583					$	130,696					7.2		%				—						0.1		%				7.1		%

(1) Reported revenue growth and organic revenue growth may not recalculate due to rounding.

CAG Diagnostics Recurring Revenue. The increase in CAG Diagnostics recurring revenue was primarily due to higher volumes in IDEXX VetLab consumables and reference laboratory testing, partially offset by macroeconomic and sector headwinds, and higher realized prices offsetting inflationary cost impacts.

The increase in IDEXX VetLab consumables revenue was primarily due to higher volume and price realization. Volume gains were supported by the benefits from 10% growth in our active installed base of premium instruments, which reflected new customers and continued high customer retention rates, and our expanded menu of available tests. The change in foreign currency exchange rates did not have a significant impact on revenue growth.

The decrease in rapid assay revenue resulted primarily from a shift of customers’ pancreatic lipase testing to our Catalyst instrument platform, as well as lower clinical visits in the U.S., partially offset by higher price realization. The change in foreign currency exchange rates decreased revenue growth by 0.1%.

The increase in reference laboratory diagnostic and consulting services revenue was due to higher global price realization and higher testing volumes in the U.S., Europe, and Asia Pacific. The change in foreign currency exchange rates increased revenue growth by 0.1%.

The increase in CAG Diagnostics services and accessories revenue was primarily a result of growth in our active installed base of premium instruments.

CAG Diagnostics Capital – Instrument Revenue. The increase in instrument revenue was primarily due to placements of our recently launched IDEXX inVue Dx Analyzer, partially offset by lower placements of other premium instruments. The change in foreign currency exchange rates decreased revenue growth by 0.4%.

Veterinary Software, Services and Diagnostic Imaging Systems Revenue. The increase in recurring revenue was primarily due to higher subscription and support services volume from our expanded installed base and from higher realized prices. The increase in our systems and hardware revenue was primarily due to higher diagnostic imaging system sales. The change in foreign currency exchange rates decreased revenue growth by 0.2%. Acquisitions increased revenue growth by 0.9%.

The following table presents the CAG segment results of operations:

						For the Six Months Ended June 30,																								Change
Results of Operations (dollars in thousands)						2025						Percent of Revenue						2024						Percent of Revenue						Amount						Percentage
Revenues						$	1,942,279											$	1,811,583											$	130,696					7.2		%
Cost of revenue						725,354												696,276												29,078						4.2		%
Gross profit						1,216,925						62.7		%				1,115,307						61.6		%				101,618						9.1		%
Segment operating expenses:
Sales and marketing						289,808						14.9		%				266,338						14.7		%				23,470						8.8		%
General and administrative						171,612						8.8		%				228,831						12.6		%				(57,219)						(25.0		%)
Research and development						111,873						5.8		%				98,892						5.5		%				12,981						13.1		%
Total segment operating expenses						573,293						29.5		%				594,061						32.8		%				(20,768)						(3.5		%)
Segment income from operations						$	643,632					33.1		%				$	521,246					28.8		%				$	122,386					23.5		%

Gross Profit. Gross profit increased due to higher revenue and a 110 basis point increase in the gross profit margin. The increase in the gross profit margin reflected proportionately higher IDEXX VetLab consumable volume growth and the benefit from net price realization, offsetting inflationary cost impacts. These increases in the gross profit margin were reduced by the business mix impact from high instrument revenue. The change in foreign currency exchange rates on the gross profit margin was not significant.

Segment Operating Expenses. Sales and marketing expense increased primarily due to higher personnel-related costs. General and administrative expense decreased primarily due to a $61.5 million expense in the prior year related to a litigation matter, partially offset by a related reduction in accrued expense of approximately $9 million in the first quarter of the current period and by higher personnel-related and information technology costs. Research and development expense increased primarily due to higher personnel-related costs, as well as higher project costs. The change in foreign currency exchange rates was not significant to operating expense growth.

Water

The following table presents the Water segment results of operations:

						For the Six Months Ended June 30,																								Change
Results of Operations (dollars in thousands)						2025						Percent of Revenue						2024						Percent of Revenue						Amount						Percentage
Revenues						$	96,322											$	89,797											$	6,525					7.3		%
Cost of revenue						28,738												27,226												1,512						5.6		%
Gross profit						67,584						70.2		%				62,571						69.7		%				5,013						8.0		%
Segment operating expenses:
Sales and marketing						12,107						12.6		%				11,487						12.8		%				620						5.4		%
General and administrative						7,123						7.4		%				8,631						9.6		%				(1,508)						(17.5		%)
Research and development						2,895						3.0		%				2,519						2.8		%				376						14.9		%
Total segment operating expenses						22,125						23.0		%				22,637						25.2		%				(512)						(2.3		%)
Segment income from operations						$	45,459					47.2		%				$	39,934					44.5		%				$	5,525					13.8		%

Revenue. The increase in revenue was due to higher realized prices and higher volumes. The increase in volumes was due to higher testing volumes, primarily in Europe and Asia Pacific. The change in foreign currency exchange rates decreased revenue growth by 0.6%.

Gross Profit. Gross profit increased due to higher revenue as well as a 50 basis point increase in the gross profit margin. The increase in the gross profit margin was due to higher realized prices, partially offset by higher product costs. The change in foreign currency exchange rates decreased the gross profit margin by approximately 10 basis points, including the impact of higher hedge gains during the current period compared to the prior period.

Segment Operating Expenses. Sales and marketing expense increased primarily due to higher travel and meeting costs and higher personnel-related costs. General and administrative expense decreased primarily due to lower bad debt expense and lower personnel-related costs. Research and development expense increased primarily due to higher personnel-related costs. The change in foreign currency exchange rates decreased operating expense growth by less than 1%.

Livestock, Poultry and Dairy

The following table presents the LPD segment results of operations:

						For the Six Months Ended June 30,																								Change
Results of Operations (dollars in thousands)						2025						Percent of Revenue						2024						Percent of Revenue						Amount						Percentage
Revenues						$	60,358											$	58,511											$	1,847					3.2		%
Cost of revenue						31,064												27,719												3,345						12.1		%
Gross profit						29,294						48.5		%				30,792						52.6		%				(1,498)						(4.9		%)
Segment operating expenses:
Sales and marketing						14,858						24.6		%				13,727						23.5		%				1,131						8.2		%
General and administrative						8,929						14.8		%				8,487						14.5		%				442						5.2		%
Research and development						5,887						9.8		%				6,213						10.6		%				(326)						(5.2		%)
Total segment operating expenses						29,674						49.2		%				28,427						48.6		%				1,247						4.4		%
Segment income from operations						$	(380)					(0.6		%)				$	2,365					4.0		%				$	(2,745)					(116.1		%)

Revenue. The increase in revenue was primarily due to higher realized prices and an increase in test volumes in the Americas and Asia Pacific, partially offset by lower volumes in Europe. The change in foreign currency exchange rates decreased revenue growth by 0.2%.

Gross Profit. The decrease in gross profit was primarily due to a 410 basis point decrease in the gross profit margin, partially offset by higher revenue. The decrease in the gross profit margin was primarily due to higher product and related costs, partially offset by higher realized prices. The change in foreign currency exchange rates decreased the gross profit margin by approximately 50 basis points, including the impact of lower hedge gains during the current period compared to the prior period.

Segment Operating Expenses. Sales and marketing expense increased primarily due to higher personnel-related and travel costs. General and administrative expense increased primarily due to higher personnel-related costs. Research and development expense decreased primarily due to lower personnel-related costs. The change in foreign currency exchange rates was not significant to operating expense growth.

Other

The following table presents the Other results of operations:

						For the Six Months Ended June 30,																								Change
Results of Operations (dollars in thousands)						2025						Percent of Revenue						2024						Percent of Revenue						Amount						Percentage
Revenues						$	8,925											$	7,782											$	1,143					14.7		%
Cost of revenue						4,617												4,223												394						9.3		%
Gross profit						4,308						48.3		%				3,559						45.7		%				749						21.0		%
Other operating expenses:
Sales and marketing						557						6.2		%				566						7.3		%				(9)						(1.6		%)
General and administrative						2,578						28.9		%				3,318						42.6		%				(740)						(22.3		%)
Research and development						304						3.4		%				461						5.9		%				(157)						(34.1		%)
Total Other operating expenses						3,439						38.5		%				4,345						55.8		%				(906)						(20.9		%)
Other income from operations						$	869					9.7		%				$	(786)					(10.1		%)				$	1,655					(210.6		%)

Revenue. The increase in revenue was primarily due to higher sales volumes of our OPTI Medical consumables and instruments.

Gross Profit. Gross profit increased due to higher revenues and a 260 basis point increase in the gross profit margin. The increase in the gross profit margin was largely due to lower product costs. The change in foreign currency exchange rates did not have a significant impact on the gross profit margin.

Operating Expenses. Sales and marketing expense increased due to higher personnel-related costs. General and administrative expense decreased primarily due to lower foreign currency transaction losses compared to the prior year. Research and development expense decreased due to lower activities that were not attributable to our three reportable segments.

Non-Operating Items

Interest Expense and Income. Interest expense was $19.0 million for the six months ended June 30, 2025, compared to $16.0 million for the same period during the prior year. The increase in interest expense was primarily due to higher average debt levels and, to a lesser extent, higher interest rates. Interest income was $1.8 million for the six months ended June 30, 2025, compared to $7.8 million for the same period during the prior year, primarily due to a decrease in money market investments.

Provision for Income Taxes. Our effective income tax rate was 20.2% for the six months ended June 30, 2025, compared to 20.9% for the six months ended June 30, 2024. The decrease in our effective tax rate was primarily driven by the resolution of international tax audits.

Liquidity and Capital Resources

We fund the capital needs of our business through cash on hand, funds generated from operations, proceeds from long-term senior note financings, and amounts available under our Credit Facility. We generate cash primarily through the payments made by customers for our companion animal veterinary, livestock, poultry, dairy, and water products and services, consulting services, and other various systems and services. Our cash disbursements are primarily related to compensation and benefits for our employees, inventory and supplies, repurchases of our common stock, taxes, research and development, capital expenditures, rents, occupancy-related charges, interest expense, and business acquisitions. Working capital totaled $138.5 million as of June 30, 2025, compared to $332.0 million as of December 31, 2024. The change in working capital is primarily due to lower cash balances and higher borrowings outstanding on the Credit Facility in the current year. As of June 30, 2025, we had $164.6 million of cash and cash equivalents, compared to $288.3 million as of December 31, 2024. As of June 30, 2025, we had a remaining borrowing availability of $669.1 million under our $1.25 billion Credit Facility, with $579.0 million in outstanding borrowings under the Credit Facility. As of December 31, 2024, we had $250.0 million in outstanding borrowings under the Credit Facility. The general availability of funds under our Credit Facility is reduced by $1.9 million for outstanding letters of credit. We believe that, if necessary, we could obtain additional borrowings to fund our growth objectives. We further believe that current cash and cash equivalents, funds generated from operations, and committed borrowing availability will be sufficient to fund our operations, capital purchase requirements, and anticipated growth needs for the next twelve months. We believe that these resources, coupled with our ability, as needed, to obtain additional financing, will also be sufficient to fund our business as currently conducted for the foreseeable future. We may enter into new financing arrangements or refinance or retire existing debt in the future depending on market conditions. Should we require more capital in the U.S. than is generated by our operations, for example, to fund significant discretionary activities, we could elect to raise capital in the U.S. through the incurrence of debt or equity issuances, which we may not be able to complete on favorable terms or at all. In addition, these alternatives could result in increased interest expense or other dilution of our earnings.

We manage our worldwide cash requirements considering available funds among all of our subsidiaries. Our foreign cash and cash equivalents are generally available without restrictions to fund ordinary business operations outside the U.S.

The following table presents cash and cash equivalents held domestically and by our foreign subsidiaries:

Cash and cash equivalents (dollars in thousands)						June 30, 2025						December 31, 2024
U.S.						$	18,555					$	145,118
Foreign						146,039						143,148
Total						$	164,594					$	288,266
Total cash and cash equivalents held in U.S. dollars by our foreign subsidiaries						$	12,129					$	10,623

As of June 30, 2025, of the $164.6 million of cash and cash equivalents held, $157.1 million was held as bank deposits and $7.5 million was held in a U.S. government money market fund. As of December 31, 2024, of the $288.3 million of cash and cash equivalents held, $148.7 million was held as bank deposits and $139.6 million was held in a U.S. government money market fund. Our bank deposits are held at a diversified group of institutions, primarily systemically important banks. Cash and cash equivalents as of June 30, 2025, included approximately $1.0 million in cash denominated in non-U.S. currencies held in a country with currency control restrictions, which limit our ability to transfer funds outside of the country in which they are held without incurring costs.

The following table presents additional key information concerning working capital:

			For the Three Months Ended
			June 30, 2025						March 31, 2025			December 31, 2024						September 30, 2024						June 30, 2024
Days sales outstanding (1)			44.7						45.7			47.1						48.9						47.3
Inventory turns (2)			1.5						1.3			1.3						1.3						1.4

(1) Days sales outstanding represents the average of the accounts receivable balances at the beginning and end of each quarter divided by revenue for that quarter, the result of which is then multiplied by 91.25 days.

(2) Inventory turns are calculated as the ratio of our inventory-related cost of revenue for the quarter multiplied by four, divided by the average inventory balances at the beginning and end of each quarter.

Sources and Uses of Cash

The following table presents cash provided (used):

						For the Six Months Ended June 30,
(dollars in thousands)						2025						2024						Change
Net cash provided by operating activities						$	423,705					$	446,897					$	(23,192)
Net cash used by investing activities						(63,238)						(139,851)						76,613
Net cash used by financing activities						(495,952)						(354,312)						(141,640)
Net effect of changes in exchange rates on cash						11,813						(5,076)						16,889
Net change in cash and cash equivalents						$	(123,672)					$	(52,342)					$	(71,330)

Operating Activities. Cash provided by operating activities during the six months ended June 30, 2025, was $423.7 million, which was a net decrease in operating cash flows of $23.2 million, compared to the same period during the prior year. Cash was provided from net income of $536.7 million, adjusted for net non-cash items of $111.6 million, partially offset by a net decrease from changes in operating assets and liabilities of $224.5 million. The following table presents cash flow impacts from changes in operating assets and liabilities, excluding the effects of foreign exchange rate fluctuations:

						For the Six Months Ended June 30,
(dollars in thousands)						2025						2024						Change
Accounts receivable						$	(74,889)					$	(82,981)					$	8,092
Inventories						(4,081)						(6,213)						2,132
Other assets and liabilities						(139,906)						18,783						(158,689)
Accounts payable						(12,113)						3,802						(15,915)
Deferred revenue						6,446						(526)						6,972
Total change in cash due to changes in operating assets and liabilities						$	(224,543)					$	(67,135)					$	(157,408)

Cash used by changes in operating assets and liabilities during the six months ended June 30, 2025, increased $157.4 million, compared to the same period during the prior year. During the current period, we paid approximately $80 million, which was accrued in prior years, to conclude a litigation matter and the payment is included within the cash flow impacts from changes in other assets and liabilities. Higher tax payments in the current period and an increase in contract assets arising from customer commitment arrangements, partially offset by lower annual employee incentive program payments in the current period, also contributed to the increase in cash used for other assets and liabilities, compared to the same period in the prior year.

We have historically experienced proportionately lower net cash flows from operating activities during the first quarter and proportionately higher cash flows from operating activities for the remainder of the year driven primarily by payments related to annual employee incentive programs in the first quarter following the year for which the bonuses were earned.

Investing Activities. Cash used by investing activities was $63.2 million during the six months ended June 30, 2025, compared to $139.9 million for the same period during the prior year. The decrease in cash used by investing activities was primarily due to the acquisition of a software business during the prior-year period.

Our total capital expenditure plan for 2025 is estimated to be approximately $160.0 million, which includes capital investments in manufacturing and operations facilities to support growth and efficiencies, as well as investments in customer-facing software development.

Financing Activities. Cash used by financing activities was $496.0 million during the six months ended June 30, 2025, compared to $354.3 million used for the same period during the prior year. The increase in cash used was primarily due to $739.0 million of repurchases of our common stock during the current year, compared to $370.3 million of repurchases during the prior year, as well as a payment upon the maturity of our 2025 Series C Notes equivalent to $103.4 million. This increase in cash used by financing activities was partially offset by $329.0 million in net borrowings under our Credit Facility during the current year, compared to no activity under our Credit Facility during the prior-year period. We also remitted approximately $8.4 million of excise tax related to the repurchase of our common stock on April 15, 2025, which is included in the repurchases of common stock on our cash flow statement.

We believe that the repurchase of our common stock is a favorable means of returning value to our stockholders, and we also repurchase our stock to offset the dilutive effect of our share-based compensation programs. Repurchases of our common stock may vary depending upon the level of other investing and deployment activities, as well as share price and prevailing interest rates, and are subject to market conditions. Refer to Note 12 to the unaudited condensed consolidated financial statements in “Part I. Item 1. Financial Statements” of this Quarterly Report on Form 10-Q for additional information about our share repurchases.

As of June 30, 2025, we had $579.0 million in outstanding borrowings under the Credit Facility, of which $250.0 million is outstanding borrowings under our term loan that matures on October 20, 2025. We anticipate paying off our term loan when due in October 2025, with available cash on hand, borrowings under our line of credit, or a combination thereof. The obligations under our Credit Facility may be accelerated upon the occurrence of an event of default under the Credit Facility, which includes customary events of default including payment defaults, defaults in the performance of the affirmative, negative and financial covenants, the inaccuracy of representations or warranties, bankruptcy and insolvency-related defaults, defaults relating to judgments, certain events related to employee pension benefit plans under the Employee Retirement Income Security Act of 1974 (“ERISA”), the failure to pay specified indebtedness, cross-acceleration to specified indebtedness, and a change of control default. The Credit Facility contains affirmative, negative, and financial covenants customary for financings of this type. The negative covenants include restrictions on liens, indebtedness of subsidiaries of the Company, fundamental changes, investments, transactions with affiliates, certain restrictive agreements, and violations of laws and regulations. The sole financial covenant is a consolidated leverage ratio test as described below.

The aggregate principal amounts of our 2025 Series B Notes will become due and payable on December 11, 2025. We anticipate paying off our 2025 Series B Notes for $75.0 million when due in December 2025, with available cash on hand, borrowings under our Credit Facility, or proceeds from the issuance of new notes, or a combination thereof.

Should we elect to prepay any of our senior notes, such aggregate prepayment will include the applicable make-whole amount(s), as defined within the applicable Senior Note Agreements. Additionally, in the event of a change in control of the Company or upon the disposition of certain assets of the Company, the proceeds of which are not reinvested (as defined in the Senior Note Agreements), we may be required to prepay all or a portion of the senior notes. The obligations under the senior notes may be accelerated upon the occurrence of an event of default under the applicable Senior Note Agreements, each of which includes customary events of default including payment defaults, defaults in the performance of the affirmative, negative and financial covenants, the inaccuracy of representations or warranties, bankruptcy and insolvency-related defaults, defaults relating to judgments, certain events related to employee pension benefit plans under ERISA, the failure to pay specified indebtedness, cross-acceleration to specified indebtedness, and a change of control default. The Senior Note Agreements contain affirmative, negative, and financial covenants customary for agreements of this type. The negative covenants include restrictions on liens, indebtedness of our subsidiaries, priority indebtedness, fundamental changes, investments, transactions with affiliates, certain restrictive agreements, and violations of laws and regulations. The sole financial covenant is a consolidated leverage ratio test as described below.

Effect of Currency Translation on Cash. The net effect of changes in foreign currency exchange rates is related to changes in exchange rates between the U.S. dollar and the functional currencies of our foreign subsidiaries. These changes will fluctuate for each period presented as the value of the U.S. dollar relative to the value of foreign currencies changes. A currency’s value depends on many factors, including interest rates and the issuing governments’ debt levels and strength of economy.

Off-Balance Sheet Arrangements. We have no off-balance sheet arrangements or variable interest entities, except for letters of credit and third-party guarantees.

Financial Covenant. The sole financial covenant of our Credit Facility and Senior Note Agreements is a consolidated leverage ratio test that requires our ratio of debt to earnings before interest, taxes, depreciation and amortization, non-recurring transaction expenses incurred in connection with acquisitions, share-based compensation expense, and certain other non-cash losses and charges (“Adjusted EBITDA”), as defined in the Senior Note Agreement and Credit Facility, not to exceed 3.5-to-1. As of June 30, 2025, we were in compliance with such covenant. The following details our consolidated leverage ratio calculation:

(dollars in thousands)			Twelve Months Ended
Trailing 12 Months Adjusted EBITDA:			June 30, 2025
Net income attributable to stockholders			$	985,656
Interest expense			34,182
Provision for income taxes			242,076
Depreciation and amortization			137,674
Acquisition-related expense			—
Share-based compensation expense			59,645
Extraordinary and other non-recurring non-cash charges			—
Adjusted EBITDA			$	1,459,233
Debt to Adjusted EBITDA Ratio:			June 30, 2025
Line of Credit			$	579,000
Current and long-term portions of long-term debt			524,806
Total debt			1,103,806
Acquisition-related contingent consideration payable			1,787
Deferred financing costs			194
Gross debt			$	1,105,787
Gross debt to Adjusted EBITDA ratio			0.76
Less: Cash and cash equivalents			$	164,594
Net debt			$	941,193
Net debt to Adjusted EBITDA ratio			0.64

Adjusted EBITDA, gross debt, net debt, gross debt to Adjusted EBITDA ratio, and net debt to Adjusted EBITDA ratio are non-GAAP financial measures which should be considered in addition to, and not as a replacement for, financial measures presented according to U.S. GAAP. Management believes that reporting these non-GAAP financial measures provides supplemental analysis to help investors further evaluate our business performance and available borrowing capacity under our Credit Facility.

Other Commitments, Contingencies and Guarantees

Significant commitments, contingencies, and guarantees as of June 30, 2025, are described in Note 16 to the unaudited condensed consolidated financial statements in “Part I. Item 1. Financial Statements” of this Quarterly Report on Form 10-Q.